Desert Gold: Exploration stock for the gold comeback
Gold is in crisis mode. For a long time, the precious metal held above the USD 4,000 per troy ounce mark. The subsequent decline was all the more dramatic, with prices falling below USD 3,700 in less than two weeks. Despite the sharp price falls, precious metals expert Markus Bußler from the investment magazine “Der Aktionär” increasingly sees signs that a bottom may be forming. The latest wave of selling was likely driven primarily by interest rate fears, liquidity-driven selling and automated trading strategies. Yet fundamental conditions have, if anything, improved recently. Falling oil prices point to easing inflationary pressure, while US bond yields remain below their autumn highs. The sharp correction could therefore be an overreaction and an expression of a final capitulation phase.
The relative strength of major gold producers is particularly encouraging. Shares such as Newmont and B2Gold continue to hold their July lows. A similar pattern emerged in 2015, when numerous gold mining stocks bottomed out well before precious metal prices. The heavily oversold technical position also points to increasing recovery potential. Despite the challenging market phase, Bußler remains invested and is betting on a rebound.
For a gold explorer, Desert Gold Ventures’ shares have held up remarkably well during the commodities sector sell-off in recent weeks. There is a good reason for this. The Canadian company is on the verge of transitioning from explorer to gold producer. At its SMSZ project in Mali, Desert Gold is pushing ahead with establishing an initially small gold production operation. In the Barani East area, a processing plant with a capacity of 200 tonnes of ore per day is due to start operating. Commercial production is targeted by the end of the first quarter of 2027. A gradual expansion to 1,200 tonnes per day is planned thereafter. This could enable Desert Gold to generate its own revenue from gold extraction for the first time and finance further exploration, at least in part, itself. This takes on even greater importance against the backdrop of rising interest rates.
At the SMSZ project, which covers more than 440 km², Desert Gold already has gold resources totalling around 1.2 million ounces. CEO Jared Scharf sees good prospects for significantly increasing these through further drilling. He considers more than 2 million ounces achievable in the medium term, and even over 5 million ounces in the long term. An initial 20,000 m drill programme is due to begin in early 2027. Desert Gold could also deliver positive surprises outside Mali. In Côte d’Ivoire, the company holds Tiegba, an exploration area covering around 300 km². A large gold anomaly has already been identified there, which has not yet been investigated by drilling. The proximity to existing gold mines increases the project’s appeal. Alongside the start of production in Mali, new drilling results and a growing resource base could therefore drive Desert Gold’s share price.
GBC Research also sees considerable share price upside for Desert Gold Ventures. The analysts recommend buying and set a price target of CAD 0.93 or EUR 0.59. Given the current price of EUR 0.077, the experts therefore see potential for Desert Gold’s shares to rise severalfold. The combination of potential near-term revenue from gold production and long-term resource growth could give the shares fresh momentum.
Deutz: From defence play to problem child
Deutz has gone from being the stock market’s celebrated defence play to a problem child. Since the beginning of September, the shares have fallen from a multi-year high of over EUR 13 to below EUR 8. The Cologne-based engine manufacturer had thrilled investors with its strategic shift towards the defence industry. With its roughly EUR 1.6 billion acquisition of Flensburger Fahrzeugbau Gesellschaft (FFG), Deutz aims to become a major supplier of military vehicles and propulsion systems. But questions are now mounting. The financing of the multibillion-euro acquisition, rising debt and the issuance of numerous new shares have dampened the euphoria. Yet the operating business is performing quite well. In the first nine months of 2026, revenue rose 11% to EUR 1.67 billion. Adjusted EBIT increased by 36% to EUR 118 million. Nevertheless, the capital market appears increasingly doubtful that the ambitious growth strategy will also create the hoped-for added value for shareholders.
A short-seller attack by Ningi Research on Wednesday added further fuel to the fire. The US short seller is betting on falling Deutz share prices and is making serious allegations about the FFG acquisition. It alleges that Deutz withheld material information about the ownership structure of the subsidiary FFG Industries. This is said to be a key growth driver, with a 45% stake held by a former Ukrainian member of parliament or his company. According to Ningi, this minority shareholder could have considerable influence over key decisions and profit distribution. The short seller is therefore also questioning the revenue and earnings contributions Deutz expects from the acquisition. The contentious point, it says, is that Deutz has to shoulder the financing, while a substantial proportion of the profits could be due to other shareholders. The allegations have not yet been independently confirmed. Deutz announced that it would examine the report carefully and respond based on the facts. Investors nevertheless reacted by selling. On Wednesday, the shares plunged by around 16% at one point to EUR 7.48. Yesterday, the share price stabilised and edged up to EUR 7.84.
Evotec: Positive news leaves investors cold
Just how poor stock market sentiment currently is became apparent at Evotec on Thursday. The biotechnology group reported another success in its collaboration with US pharmaceutical giant Bristol Myers Squibb. The badly battered shares rose more than 3% in the morning, but the gains evaporated as trading continued. In the afternoon, the share price even slipped into negative territory. Apparently, concerns about the company’s economic performance continue to dominate among many investors.
Evotec and Bristol Myers Squibb have received the green light from the US Food and Drug Administration (FDA) for a second jointly developed drug candidate. This means the so-called CELMoD compound, designed to target the degradation of disease-related proteins, can move into clinical trials. A Phase 1 trial is scheduled to begin in 2027. A first candidate from the partnership entered clinical development in March 2026. It is being studied in patients with advanced renal cell carcinoma. The collaboration has been in place since 2018 and has since been expanded. Evotec contributes its AI-powered research platforms, while Bristol Myers Squibb provides its extensive compound library. The latest clearance shows that the joint research is indeed producing new drug candidates. However, this is still a long way from drug approval.
The partnership could have considerable long-term economic significance for Evotec. Further milestone payments are possible as development progresses. However, the current FDA clearance does not yet trigger any payment.
Conclusion
With Deutz, one should wait for a bottom to form. Defence stocks are under pressure at present anyway, and the acquisition is apparently harder for Deutz to manage than expected. Desert Gold is on the verge of becoming a gold producer. In GBC Research’s view, the shares are far too cheap. The fact that investors used yesterday’s Evotec news more as an opportunity to sell shows that there is currently no compelling reason to buy.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
